Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS…